 Study using induced blood stage malaria infection to characterize the activity of MMV390048 against early Plasmodium falciparum blood stage infection. There will be two or more cohorts of 8 subjects. In the first cohort a single dose of 20 mg of MMV390048 will be investigated. Depending on the data obtained, the dose in Cohort 2 may be adjusted but will not exceed the maximum tolerated dose or highest achieved dose based on a predefined exposure cap as determined in an ongoing single ascending dose study. Each participant will be inoculated on Day 0 with 1,800 viable parasites of Plasmodium falciparum-infected human erythrocytes intravenously. On an outpatient basis, participants will be monitored daily until positive for presence of malaria parasites. Once positive they will be monitored twice-daily until treatment, for adverse events and the unexpected early onset of symptoms, signs or parasitological evidence of malaria. On the day designated for commencement of treatment, participants will be admitted to the study unit and monitored. The threshold for commencement of treatment will be when quantification of all participants is 1,000 parasitesmL. If the quantification of any participant is 5,000 parasitesmL, and is accompanied by a clinical symptom score 5, or if clinical or parasitological evidence of malaria occurs in any participant before all participants have reached the treatment threshold quantification of 1,000, then treatment of that participant will begin within a 24 h period. 